News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|September 1, 2002

Supplements and Featured Publications

Cost Utilization Analysis of Inhaled Steroids for Allergic Rhinitis Management
Volume 8
Issue 13 Suppl

Assessment of Intranasal Corticosteroid Use in Allergic Rhinitis: Benefits, Costs, and Patient Preferences

Author(s)Leon Dupclay, Jr., PharmD, Joseph Doyle, RPh, MBA

Download PDF: Assessment of Intranasal Corticosteroid Use in Allergic Rhinitis: Benefits, Costs, and Patient Preferences

Articles in this issue

almost 24 years ago

Article

Participating Faculty

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

AJMC original research clinical

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

AJMC original research policy

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

AJMC original research managerial

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

AJMC Letter to the Editor

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

AJMC original research policy

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access